15 results
DEF 14A
CGTX
Cognition Therapeutics Inc
25 Apr 22
Definitive proxy
5:28pm
Anthony Caggiano, M.D., Ph.D. to the newly combined position of Chief Medical Officer and head of R&D to oversee the completion of Phase 2 clinical … of the key functions of our Board is to oversee our risk management process. Our Board does not have a standing risk management committee but rather
S-1
CGTX
Cognition Therapeutics Inc
19 Jul 21
IPO registration
7:02am
NDA approval in the United States as well as any term limitations based upon earlier expiring patents.
Manufacturing Strategy
We oversee and manage … Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research
DRS
l4o8316m8diteaxa
7 May 21
Draft registration statement
12:00am
DRS/A
r2g3gam9ni
23 Jun 21
Draft registration statement (amended)
12:00am
424B4
y58cd57q3mdy30r
12 Oct 21
Prospectus supplement with pricing info
4:11pm
424B4
gp3t4kqtw
14 Nov 22
Prospectus supplement with pricing info
6:02am
10-K
90kk4a9ayo7wmwrxbw
30 Mar 22
Annual report
7:40am
DRS
ow1qy
20 Oct 22
Draft registration statement
12:00am
- Prev
- 1
- Next